The return of ultra-thin fashion imagery and the growing visibility of weight-loss drugs have renewed scrutiny of how much progress the body-positivity movement achieved, as runway figures show the continued dominance of straight-size models.
A 30 October 2026 analysis by The Guardian examined the contrast between the language of self-acceptance popularised during the late 2010s and a fashion culture in which slimness remains highly rewarded. The article, by Hannah Marriott, was headlined 'Everyone is thin and we're not allowed to say so: the toxic legacy of body positivity.'
The discussion comes amid growing attention to GLP-1 medicines, which are used to treat conditions including type 2 diabetes and, in some cases, obesity, alongside continued concerns about the narrow range of sizes represented on luxury catwalks.
Runway Figures Show Limited Size Diversity
The Guardian cited Vogue Business research showing that 97.5% of looks presented during the spring/summer 2027 fashion season were modelled by straight-size models (US sizes 0-4). The remaining 2.5% comprised mid-size and plus-size looks, with the latter accounting for just 0.5% of the total. The figures count runway looks, not unique models.
Earlier tracking suggested that size representation had made limited gains. The Fashion Spot recorded just six plus-size model appearances during the autumn 2016 season, compared with 103 appearances, representing 2.34% of total castings, in autumn 2022. Vogue Business began tracking runway size diversity in 2023 and subsequently reported a decline in mid-size and plus-size representation.
Those datasets should not be treated as directly interchangeable. They use different definitions and cover different periods, but both show that plus-size representation has remained a small share of luxury runway casting.
The renewed debate also concerns the difference between models appearing in campaigns and clothing actually being available in their sizes. Some designers have featured plus-size models in campaigns and runway presentations without consistently offering corresponding clothing sizes to customers.
From Body Positivity to Body Neutrality
Body positivity has roots in fat liberation and fat-acceptance activism, as well as broader movements advocating bodily autonomy, before gaining mainstream commercial popularity. During the late 2010s, advertising increasingly featured messages about self-love and a wider range of body types.
Tigress Osborn, chair of the National Association to Advance Fat Acceptance (NAAFA), said the movement was rooted in fat liberation and bodily autonomy, including the principle that individuals should have control over their own bodies. Its advocates have also challenged discrimination and barriers faced by people in larger bodies.
Its commercial popularity drew criticism from activists who argued that brands had adopted its language without making meaningful changes to representation, clothing sizes and industry practices. Advertising messages about acceptance did not necessarily mean customers could buy the featured designs in their sizes.
Body neutrality subsequently gained attention as another approach. Rather than requiring people to view their bodies as beautiful, it encourages them to place less emphasis on appearance when determining their self-worth. The approaches are not necessarily mutually exclusive.
GLP-1 Drugs Enter the Fashion Conversation
Medicines such as semaglutide and tirzepatide have become increasingly prominent in public discussions about weight management. Ozempic is a brand name for semaglutide, while Mounjaro is a brand name for tirzepatide. Neither should be used as a blanket term for all GLP-1 treatments or weight-loss medication.
The Guardian also examined criticism of pharmaceutical sponsorship at fashion events. Eli Lilly, which manufactures medicines including Mounjaro and Zepbound, faced criticism over its sponsorship of Vogue World: Milano, with the company defending the partnership as an opportunity to encourage conversations about weight and health.
Critics argued that the partnership was inconsistent with efforts to promote greater body diversity in fashion. Eli Lilly, meanwhile, said its collaboration with Vogue was intended to encourage discussions about health and challenge the stigma surrounding obesity.
Online discussions increasingly use terms such as 'toned', 'strong,' and 'snatched' to describe appearance, while openly expressing a desire to be thin remains socially contentious. Social media users also encounter fitness, beauty, and weight-management content that may present different or conflicting expectations about bodies.
Debate Over What Inclusion Means
The current debate centres on fashion casting, the range of clothing sizes offered by brands and the language used to discuss bodies. It also raises questions about respecting individual decisions regarding weight without reinforcing thinness as a universal ideal.
The Guardian's analysis highlighted the tension between public messages of body acceptance and the fashion industry's continued preference for thin models. Runway statistics offer one measure of representation, while clothing availability provides another.
As fashion houses prepare new collections, the share of different body sizes on the catwalk and the availability of clothes beyond sample sizes remain concrete measures by which their stated commitments can be assessed.
